Efficacy of the novel antidepressant agomelatine on the circadian rest activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline / Siegfried Kasper en The Journal of Clinical Psychiatry, Año 2010 - Vol. 71 - No. 2 (Febrero)

Público ISBD [artículo]  inThe Journal of Clinical Psychiatry > Año 2010 - Vol. 71 - No. 2 (Febrero) . - pp. 109-120 Título : Efficacy of the novel antidepressant agomelatine on the circadian rest activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline Tipo de documento: texto impreso Autores: Siegfried Kasper, Autor ; Göran Hajak, Autor ; Katharina Wulff, Autor Fecha de publicación: 2022 Artículo en la página: pp. 109-120 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Antidepresivos, Ansiedad, Ritmo circadiano, Depresión, Trastorno depresivo mayor, Actividad motora, Descansar, Sertralina, Índice de gravedad de la enfermedad, Efectos del sueño. Resumen: This study evaluates the efficacy of agomelatine, the first antidepressant to be an agonist at MT(1)/MT(2) receptors and an antagonist at 5-HT(2C) receptors, versus sertraline with regard to the amplitude of the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder (MDD). Link: ./index.php?lvl=notice_display&id=28130 [artículo] Efficacy of the novel antidepressant agomelatine on the circadian rest activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline [texto impreso] / Siegfried Kasper, Autor ; Göran Hajak, Autor ; Katharina Wulff, Autor . - 2022 . - pp. 109-120. Idioma : Inglés (eng) Idioma original : Inglés (eng) in The Journal of Clinical Psychiatry > Año 2010 - Vol. 71 - No. 2 (Febrero) . - pp. 109-120 Palabras clave: Antidepresivos, Ansiedad, Ritmo circadiano, Depresión, Trastorno depresivo mayor, Actividad motora, Descansar, Sertralina, Índice de gravedad de la enfermedad, Efectos del sueño. Resumen: This study evaluates the efficacy of agomelatine, the first antidepressant to be an agonist at MT(1)/MT(2) receptors and an antagonist at 5-HT(2C) receptors, versus sertraline with regard to the amplitude of the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder (MDD). Link: ./index.php?lvl=notice_display&id=28130

---

1 (1 - 1 / 1)